We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Disease Genes Effect May Be Overcome by Other Gene Mutations

By Michal Siman-Tov
Posted on 15 Nov 2016
A first-of-its-kind study, performed in the model yeast Saccharomyces cerevisiae, shows how “bad genes aren’t always bad news” in that the disease-causing effects of mutations in certain genes can be overcome by suppression-mutations in certain other genes. More...
The study opens a new way for better understanding how some people naturally stay healthy despite having disease-causing mutations, and potentially a new path to better diagnostics and therapies of genetic disorders.

Though little has been known about the mechanisms of genetic suppression, researchers are uncovering the general rules behind it. An international team of researchers led by Professors Brenda Andrews, Charles Boone, and Frederick Roth of the University of Toronto School of Medicine (Toronto, Ontario, Canada) and Professor Chad Myers of the University of Minnesota-Twin Cities (Minneapolis, MN, USA) have compiled the first comprehensive set of suppressive mutations in a cell. Their findings could help explain how suppressive mutations combine with disease-causing mutations to reduce or even prevent a genetic disorder.

This curious bit of biology has come to light as increasing numbers of healthy people have had their genomes sequenced. Among them are a few who remain healthy despite carrying catastrophic mutations that usually cause debilitating disorders, such as Cystic Fibrosis or Fanconi anemia.

“We don’t really understand why some people with damaging mutations get the disease and some don’t. Some of this could be due to environment, but a lot of could be due to the presence of other mutations that are suppressing the effects of the first mutation,” said Prof. Roth. Certain suppression mutations can keep cells healthy despite otherwise damaging mutations. “If we know the genes in which these suppressive mutations occur, then we can understand how they relate to the disease-causing genes and that may guide future drug development,” said first author Dr. Jolanda van Leeuwen.

“A study like this has never been done on a global scale. And since it is not possible to do these experiments in humans, we used yeast as a model organism, in which we can know exactly how mutations affect the cell’s health,” said Dr. Van Leeuwen.

The researchers took a two-pronged approach. On the one hand, they analyzed all published data on known suppressive relationships between yeast genes. While informative, these results were inevitably skewed towards the most popular genes – the ones scientists have already studied in detail. So they also carried out an unbiased analysis by experimentally measuring how well the cells grew when they carried a damaging mutation on its own, or in combination with another mutation.

Because harmful mutations slow down cell growth, any improvement in growth rate was due to the suppressive mutation in a second gene. These experiments revealed hundreds of suppressor mutations for the known damaging mutations. Importantly, regardless of the approach, the data point to the same conclusion: to find suppressor genes, there is often no need to look far from the genes with damaging mutations. The genes tend to have related roles in the cell – mainly either that their protein products are physically located in the same place, or that they work in the same molecular pathway.

“We’ve uncovered fundamental principles of genetic suppression and show that damaging mutations and their suppressors are generally found in genes that are functionally related. Instead of looking for a needle in the haystack, we can now narrow down our focus when searching for suppressors of genetic disorders in humans,” said Prof. Boone.

The study, by van Leeuwen J, Pons C, et al, was published November 4, 2016, in the journal Science.

Related Links:
University of Toronto School of Medicine
University of Minnesota-Twin Cities

New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Collection and Transport System
PurSafe Plus®
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.